Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 8:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 44 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Spravato (Esketamine) Clear all
Completed No phase listed Observational Accepts healthy volunteers

Intranasal Esketamine to Maintain the Antidepressant Response to IV Racemic Ketamine

NCT04856124
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Intranasal esketamine
Drug
Lead sponsor
Psych Atlanta
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Marietta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 22, 2021 · Synced Sep 28, 2026, 8:03 AM EDT
Recruiting No phase listed Observational

Retrospective Analyses of the Greenbrook Database Evaluating Mental Health Treatments

NCT06997549
View directory record Official record
Conditions
Depression, OCD, Anxiety Depression
Interventions
Patients treated with NeuroStar TMS, Patients treated with Esketamine
Device · Drug
Lead sponsor
Neuronetics
Other
Eligibility
5 Years to 100 Years
Enrollment
12,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
1
States / cities
Malvern, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Sep 28, 2026, 8:03 AM EDT
Completed Phase 2 Interventional Results available

A Double-blind Study to Assess the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Participants Who Are Assessed to be at Imminent Risk for Suicide

NCT02133001
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Esketamine, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
14
States / cities
Birmingham, Alabama • San Diego, California • Hartford, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 28, 2026, 8:03 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for Suicide

NCT03185819
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Intranasal Placebo, Midazolam Placebo Solution, Midazolam, Esketamine
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
9 Years to 17 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
18
States / cities
Hartford, Connecticut • New Haven, Connecticut • Atlanta, Georgia + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 28, 2026, 8:03 AM EDT
Completed Phase 4 Interventional Results available

A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression

NCT04599855
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant
Interventions
Esketamine 56 mg, Esketamine 84 mg, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
477 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
54
States / cities
Birmingham, Alabama • Huntsville, Alabama • Little Rock, Arkansas + 44 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2025 · Synced Sep 28, 2026, 8:03 AM EDT
Recruiting Phase 3 Interventional

A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression

NCT07716098
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant
Interventions
Esketamine 56 mg, Esketamine 84 mg, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
7
States / cities
Redlands, California • San Diego, California • Marietta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Sep 28, 2026, 8:03 AM EDT
Recruiting Phase 4 Interventional

Long-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression

NCT05450432
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Ketamine, Esketamine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Sep 28, 2026, 8:03 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression

NCT01998958
View directory record Official record
Conditions
Treatment Resistant Depressive Disorder
Interventions
Esketamine 14 mg, Esketamine 28 mg, Esketamine 56 mg, Esketamine 84 mg, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
20 Years to 64 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
14
States / cities
Birmingham, Alabama • Garden Grove, California • Hartford, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 28, 2026, 8:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine

NCT02606084
View directory record Official record
Conditions
Renal Impairment, Healthy
Interventions
Esketamine
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
2
States / cities
Miami, Florida • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 26, 2025 · Synced Sep 28, 2026, 8:03 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

National Pregnancy Registry for Psychiatric Medications

NCT01246765
View directory record Official record
Conditions
Pregnant Women, Psychotropic Drugs
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2033
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Sep 28, 2026, 8:03 AM EDT
Recruiting Phase 3 Interventional

PCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study

NCT06713616
View directory record Official record
Conditions
Depression
Interventions
Racemic ketamine, Spravato (Esketamine)
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
8
States / cities
Milford, Connecticut • New Haven, Connecticut • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 28, 2026, 8:03 AM EDT
Completed Phase 3 Interventional Results available

54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide

NCT03097133
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Esketamine, Placebo, Standard of Care
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
18
States / cities
San Diego, California • Farmington, Connecticut • Miami, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 28, 2026, 8:03 AM EDT
Completed Phase 3 Interventional Results available

A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression

NCT02782104
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant
Interventions
Esketamine Nasal Spray
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
1,148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
51
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Garden Grove, California + 48 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 28, 2026, 8:03 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

NCT02417064
View directory record Official record
Conditions
Treatment-resistant Depression
Interventions
Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
37
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Garden Grove, California + 34 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 28, 2026, 8:03 AM EDT
Completed Phase 3 Interventional Results available

54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide

NCT03039192
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Esketamine, Placebo, Standard of Care
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
17
States / cities
Birmingham, Alabama • Chandler, Arizona • Garden Grove, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 28, 2026, 8:03 AM EDT
Withdrawn Phase 1 Interventional

A Study to Assess Feasibility of Using Clinician-directed and Digital Application Supported Cognitive Behavior Therapy (CBT) in Conjunction With Esketamine in Participants With Treatment-resistant Depression

NCT05268497
View directory record Official record
Conditions
Depression
Interventions
Esketamine, Cognitive Behavioral Therapy (CBT), Antidepressant
Drug · Behavioral
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
5
States / cities
New Haven, Connecticut • Chicago, Illinois • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2025 · Synced Sep 28, 2026, 8:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Pharmacokinetics of Intranasally Administered Esketamine in Healthy Japanese and Caucasian Volunteers

NCT01980303
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Esketamine
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
20 Years to 55 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jan 27, 2014 · Synced Sep 28, 2026, 8:03 AM EDT
Completed Phase 3 Interventional Results available

A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression

NCT02493868
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant
Interventions
Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
719 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
53
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 50 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 28, 2026, 8:03 AM EDT
Completed Not applicable Interventional Results available

Using Virtual Reality to Control the Audio-visual Inputs During Ketamine/Esketamine Treatment

NCT06139016
View directory record Official record
Conditions
Depression
Interventions
Virtual reality
Device
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 28, 2026, 8:03 AM EDT
Terminated Not applicable Interventional Results available

Role Of Non-Specific Effects in The Treatment of Depression With Esketamine

NCT05910775
View directory record Official record
Conditions
Depressive Episode
Interventions
Pre and Post Treatment Presentations
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Sep 28, 2026, 8:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Mass Balance Study With a Microtracer Dose of 14C-esketamine in Healthy Male Participants

NCT02674295
View directory record Official record
Conditions
Healthy
Interventions
Esketamine 50 mg, Esketamine 20 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Sep 28, 2026, 8:03 AM EDT
Completed Phase 3 Interventional Results available

A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression

NCT02497287
View directory record Official record
Conditions
Treatment-resistant Depression
Interventions
Esketamine (Intranasal Spray), Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
802 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
16
States / cities
New Haven, Connecticut • Miami, Florida • Marietta, Georgia + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 28, 2026, 8:03 AM EDT
Recruiting No phase listed Observational

ATLAS-1: Advanced Trial for Longitudinal Assessment in Salma 1

NCT07528014
View directory record Official record
Conditions
Depressed Mood
Interventions
Not listed
Lead sponsor
Salma Health, Inc.
Other
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2037
U.S. locations
2
States / cities
La Jolla, California • Laguna Hills, California
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Sep 28, 2026, 8:03 AM EDT
Withdrawn Phase 4 Interventional

VA Aripiprazole vs Esketamine for Treatment Resistant Depression

NCT05554627
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Esketamine, Aripiprazole
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 74 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
26
States / cities
Tuscaloosa, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2024 · Synced Sep 28, 2026, 8:03 AM EDT